Lp(a) meeting The prevalence of clinical FH was investigated in the Copenhagen General Population Study with adjustment for the cholesterol content in Lp(a). Prof. Nordestgaard shares possible ways to interpret these results.
This lecture by Børge Nordestgaard was part of the EAS-endorsed satellite meeting "The imminent danger of Lp(a): Time to face the challenge" held prior to the 87th EAS congress in Maastricht
Prof. Børge Nordestgaard, MD - Professor, University of Copenhagen, Denmark/ Chief Physician, Dept. Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital Denmark
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenters and do not necessarily reflect the views of PACE-cme.
Funding for this educational program was provided by an unrestricted educational grant from Amgen and Novartis.The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
- The Imminent danger of Lp(a): Time to face to challengeLp(a) apheresis and CVD risk modulation
Elisa Waldmann, MD
- The Imminent danger of Lp(a): Time to face to challengeAre we ready for prime-time Lp(a) assay standardization?
Prof. Santica Marcovina
- The Imminent danger of Lp(a): Time to face to challengeAssociations of Lp(a) with CV morbidity and mortality
Pia Kamstrup, MD, PhD
- The Imminent danger of Lp(a): Time to face to challengeLp(a) and calcification in aortic stenosis
Kang He Zheng, MD